ANDROGEN RECEPTORS IN ENDOCRINE-THERAPY-RESISTANT HUMAN PROSTATE-CANCER
ANDROGEN RECEPTORS IN ENDOCRINE-THERAPY-RESISTANT HUMAN PROSTATE-CANCER
复制标题
DOI：
10.1002/ijc.2910480206
复制
发表时间：
1991-05-10
影响因子：
6.4
通讯作者：
TRAPMAN, J
中科院分区：
文献类型：
--
作者：
VANDERKWAST, TH;SCHALKEN, J;TRAPMAN, J
尽管大多数人前列腺癌的初始雄激素依赖性生长，但最终所有前列腺癌在雄激素消融或抗雄激素治疗后以不同的间隔变为雄激素非依赖性。 为了更深入地了解雄激素受体（AR）在这一过程中的作用，AR和前列腺特异性抗原（PA）的表达进行了评估，前列腺肿瘤组织中的患者谁开发的尿流阻塞4和107个月之间的治疗开始。 用对人AR的N-末端结构域具有特异性的单克隆抗体（MAb）评价AR表达。 为了证实进行性肿瘤生长，通过用MAb Ki-67染色以免疫化学方法评估增殖活性。 Ki-67定义的肿瘤生长分数为0.8- 64.7%。 在13的17个检查肿瘤中，超过80%的肿瘤细胞是AR阳性的，3个肿瘤显示出相当大的异质性AR表达，在1个肿瘤中几乎所有的肿瘤细胞似乎是AR阴性的。 三分之二的检查肿瘤含有不同比例的PA阳性肿瘤区域。 这些观察结果与雄激素消融诱导受体阴性肿瘤细胞优先生长的观点形成对比。
Despite the initial androgen-dependent growth of most human prostate cancers, eventually all prostate cancers become androgen-independent at varying intervals after androgen ablation or anti-androgen therapy. In order to gain more insight into the role of the androgen receptor (AR) in this process, AR and prostate-specific antigen (PA) expression was evaluated immunohistochemically in prostatic tumour tissues from patients who developed urinary flow obstruction between 4 and 107 months after onset of treatment. AR expression was evaluated with a monoclonal antibody (MAb) specific for the N-terminal domain of the human AR. To substantiate the progressive tumour growth, proliferative activity was assessed immunohistochemically by staining with MAb Ki-67. Ki-67-defined tumour-growth fractions varied from 0.8-64.7%. In 13 of the 17 examined tumours over 80% of the tumour cells were AR-positive, 3 tumours showed a considerable heterogeneity in AR expression and in 1 tumour almost all tumour cells seemed to be AR-negative. Two-thirds of the examined tumours contained variable proportions of PA-positive tumour areas. These observations contrast with the view that androgen ablation induces a preferential outgrowth of receptor-negative tumour cells.